2023 World Conference on Lung Cancer (Posters)-EP11.03. Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study

EP11.03. Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the prognostic value of body mass index (BMI) and serum lipids in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immunotherapy. The researchers collected data from patients treated at Shandong Cancer Hospital and Institute between June 2018 and February 2022. The Kaplan-Meier method and Cox's regression model were used to analyze the data.<br /><br />Among the 610 patients included in the study, 5.25% were underweight, 63.61% were normal weight, 27.21% were overweight, and 3.93% were obese. The survival analyses did not find significant differences in progression-free survival (PFS) or overall survival (OS) among patients in different BMI categories. However, overweight patients had the longest PFS (12 months) in absolute terms. The differences in PFS and OS between the low BMI group (underweight and normal weight) and high BMI group (overweight and obese) were approximately statistically significant.<br /><br />The study also explored the associations between serum lipids and outcomes. Low levels of HDL, liver metastasis, bone metastasis, other distant metastasis, and high LDH were significantly correlated with shorter PFS and OS. Age over 70 years was correlated with worse OS. Overweight status was significantly associated with better PFS and OS, while low levels of LDL were associated with improved OS. In univariate analysis, high levels of small and low-density lipoprotein (sdLDL) and serum total cholesterol (TC) were positively related to PFS and OS, while factors such as ECOG2, low albuminemia, and squamous carcinoma had adverse effects on survival.<br /><br />The study concluded that being overweight was associated with significantly prolonged survival in patients with advanced NSCLC treated with first-line immunotherapy. Additionally, low levels of HDL may be a useful marker for poor prognosis in these patients.

Asset Subtitle

Yanxin Sun

Meta Tag

Speaker Yanxin Sun

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

prognostic value

body mass index

serum lipids

non-small cell lung cancer

first-line immunotherapy

progression-free survival

overall survival

HDL

LDL

survival